Who is sponsoring NCT02605668?

NCT02605668 is sponsored by Technische Universität Dresden.

What drugs are being tested in NCT02605668?

Interventions in NCT02605668: Intensified psychological intervention, Standard intervention.

What condition does NCT02605668 study?

NCT02605668 studies Panic Disorder, Agoraphobia, Specific Phobias, Social Anxiety Disorder.

Is NCT02605668 still recruiting?

NCT02605668 is currently completed. Last updated 16 September 2019.

Last reviewed 2019-09-16 · How we verify

NCT02605668: PROTECT-AD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Providing Tools for Effective Care and Treatment of Anxiety Disorders

Completed NA Last updated 16 September 2019

What this trial tests

NA trial testing Intensified psychological intervention in Panic Disorder in 726 participants. Completed in 24 July 2019.

Timeline

12 December 2015

Primary endpoint
24 July 2019

24 July 2019

Quick facts

Lead sponsor	Technische Universität Dresden
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	726
Start date	12 December 2015
Primary completion	24 July 2019
Estimated completion	24 July 2019
Sites	1 location across Germany

Drugs / interventions tested

Intensified psychological intervention
Standard intervention

Conditions studied

Panic Disorder — all drugs for Panic Disorder →
Agoraphobia — all drugs for Agoraphobia →
Specific Phobias — all drugs for Specific Phobias →
Social Anxiety Disorder — all drugs for Social Anxiety Disorder →

Sponsor

Technische Universität Dresden — full company profile →

Who can join

Adults 15 to 70, any sex, with Panic Disorder or Agoraphobia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PROTECT-AD is a cognitive behavioral treatment study involving highly qualified psychotherapeutic centers at seven German universities. It is our goal to further investigate and optimize existing effective treatments of anxiety disorders. In order to achieve this, the investigators want to investigate the effect of extinction learning in an "intensified" psychological intervention on treatment outcome in adults and children with anxiety disorders. The intensified psychological intervention is characterized by a higher number of exposure trials over a short time period. In the control condition the exposure trials take place in a weekly interval, analog to standard care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neural adaptation of cingulate and insular activity during delayed fear extinction: A replicable pattern across assessment sites and repeated measurements
Ridderbusch IC, Wroblewski A, Yang Y, Richter J, et al · · 2020 · DOI 10.1101/2020.10.26.20218206

Verify or expand the search:

Other recruiting trials for Panic Disorder

Currently open trials in the same condition.

NCT06661460 — Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders · NA · recruiting
NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
NCT07444879 — IL-33, sST2, and CRP in Panic Disorder · recruiting
NCT07024758 — Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolesce · NA · recruiting
NCT06942429 — Stepped Versus Stratified Care for Anxiety Disorders in Youth · NA · recruiting

Other Technische Universität Dresden trials

Trials by the same sponsor.

NCT07150598 — Immune-Marker Platform for Patients With Advanced Lung Cancer · not yet recruiting
NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting
NCT06701487 — Role of Pavlovian Mechanisms for Control Over Substance Use · recruiting
NCT03865277 — Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging · Phase 2 · not yet recruiting
NCT06293170 — Automated Screening for Clinically Ascertained Loss of Cerebral Functions · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02605668 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Technische Universität Dresden
Last refreshed: 16 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02605668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing